Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicinal composition containing amlodipine and terazosine

A technology of amlodipine and terazosin, which is applied in the field of pharmacy, can solve problems such as poor curative effect and treatment delay, and achieve the effects of low production cost, large profit margin, and better and more effective effect

Inactive Publication Date: 2009-09-16
SHENZHEN AUSA PHARMA
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The composition overcomes the shortcoming that the long-acting calcium antagonist amlodipine has poor curative effect on patients with adrenoceptor α1a genotype AA homozygous wild type, effectively controls the hypertensive symptoms of this part of the population, and completely eliminates the hypertensive symptoms of this part of the population at the same time. Poor therapeutic effect of amlodipine monotherapy in blood pressure patients due to unclear adrenergic receptor gene polymorphism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing amlodipine and terazosine
  • Medicinal composition containing amlodipine and terazosine
  • Medicinal composition containing amlodipine and terazosine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 Preparation of compound amlodipine and terazosin tablets containing 3mg amlodipine and 1mg terazosin

[0038] Formulation: Amlodipine 3mg

[0039] Terazosin 1mg

[0040] Lactose 50g

[0041] Microcrystalline Cellulose 50g

[0042] Starch 10g

[0043] Sodium carboxymethyl starch 30g

[0044] Magnesium Stearate 1g

[0045] Preparation method: will contain 3mg amlodipine (using amlodipine besylate, purchased from Pfizer Pharmaceutical Co., Ltd. (Dalian, China), its dosage is converted into 3mg according to the molecular weight of amlodipine besylate and the molecular weight of amlodipine The amount of amlodipine besylate of amlodipine), 1mg terazosin (using terazosin hydrochloride, purchased from Zhejiang Huangyan Yannian Melatonin Co., Ltd., its consumption is according to the molecular weight and characteristic of terazosin hydrochloride The molecular weight of terazosin is converted into the amount of terazosin hydroc...

Embodiment 2

[0046] Example 2 Preparation of compound amlodipine and terazosin tablets containing 10mg amlodipine and 5mg terazosin

[0047] Formula: Amlodipine 10mg

[0048] Terazosin 5mg

[0049] Lactose 50g

[0050] Microcrystalline Cellulose 50g

[0051] Starch 10g

[0052] Sodium carboxymethyl starch 30g

[0053] Magnesium Stearate 1g

[0054] The preparation method is the same as in Example 1. Each of the compound tablets made contains 10 mg of amlodipine and 5 mg of terazosin, with a mass ratio of 2:1.

Embodiment 3

[0055] Example 3 Preparation of compound amlodipine and terazosin tablets containing 0.1mg amlodipine and 0.1mg terazosin

[0056] Formula: Amlodipine 0.1mg

[0057] Terazosin 0.1mg

[0058] Lactose 50g

[0059] Microcrystalline Cellulose 50g

[0060] Starch 10g

[0061] Sodium carboxymethyl starch 30g

[0062] Magnesium Stearate 1g

[0063] The preparation method is the same as in Example 1. Each of the prepared compound tablets contains 0.1 mg of amlodipine and 0.1 mg of terazosin, with a mass ratio of 1:1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing amlodipine and terazosin, belonging to the field of pharmacy. The present invention contains amlodipine, amlodipine active metabolite, amlodipine medicinal precursor or amlodipine, amlodipine active metabolite, amlodipine medicinal precursor pharmaceutically acceptable acid addition One of the salt forms; terazosin, terazosin active metabolite, terazosin pharmaceutical precursor or terazosin, terazosin active metabolite, terazosin in medicinal doses one of the pharmaceutically acceptable salts of the pharmaceutically acceptable precursor; and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition overcomes the adverse reactions of amlodipine and terazosin in single-drug application, and simultaneously, the composition has the purposes of preventing, delaying or treating hypertension, and the effect is better than that of the existing similar pharmaceutical composition. Hypertensive patients provide a drug combination suitable for practical use. Another use of the composition is in the preparation of medicaments for treating hypertensive patients accompanied by BPH.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing amlodipine and terazosin, and the use of the composition in the preparation of medicaments for treating hypertensive living organisms or hypertensive living organisms accompanied by benign prostatic hyperplasia. The present invention belongs to the field of pharmacy. Background technique [0002] Amlodipine is 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3, 5-Pyridinedicarboxylate. US Patent 4572909 discloses amlodipine and related dihydropyridine compounds which are effective antiischemic and antihypertensive agents. US Patent 4879303 discloses amlodipine besylate. US Patent 4572909 discloses amlodipine maleate. Chinese patent 03164956 discloses organic acid salts of amlodipine. Amlodipine, amlodipine besylate and other pharmaceutically acceptable acid addition salts are all effective and long-acting calcium channel antagonists, therefore,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/495A61P9/12A61P13/08A61K31/4422
Inventor 戴成祥陈光亮于多林雅军李华蒋善群王滨燕徐希平
Owner SHENZHEN AUSA PHARMA